We found a negative association between cachexia (defined based on the criteria proposed by Fearon et al.), miniCASCO-based cachexia severity, and inflammatory status (IL-6 and mGPS) and clinical outcomes (PFS and OS) in patients with advanced NSCLC undergoing ICI monotherapy. This evidence concerns the gene IL6 and non-small cell lung carcinoma.